Jiasheng Xu1, Wenpeng Zhao2, Kaili Liao3, Luxia Tu1, Xiaozhen Jiang1, Hua Dai1, Yanqing Yu1, Qiuying Xiong1, Zhenfang Xiong1. 1. Department of Pathology, The First Affiliated Hospital of Nanchang University No. 17 Yongwaizheng Street, Nanchang 330006, Jiangxi, China. 2. Department of Vascular Surgery, The Second Affiliated Hospital of Nanchang University No. 1 Minde Road, Nanchang 330006, Jiangxi, China. 3. Department of Clinical Laboratory, The Second Affiliated Hospital of Nanchang University No. 1 Minde Road, Nanchang 330006, Jiangxi, China.
Abstract
OBJECTIVE: To detect the expression of PD-L1 and K-ras gene status in colorectal cancer tissues and analyze the relationship between PD-L1 expression and the clinicopathological features and K-ras gene status in colorectal cancer. METHODS: Two hundred fifty colorectal cancer tissues were collected from the First Affiliated Hospital of Nanchang University. The normal intestinal mucosal tissues of 20 patients were randomly selected for inclusion in the control group. PD-L1 expression was detected by immunohistochemistry. K-ras gene mutation in colorectal cancer tissues was detected by sequencing. The clinical significance of PD-L1 expression and relationship between PD-L1 expression and K-ras gene mutation were analyzed. RESULTS: The immunohistochemistry assay showed that PD-L1 was highly expressed in colorectal cancer. The positive expression of PD-L1 was increased with lymph node metastasis and high TNM stage. The 5-year survival rate of PD-L1-positive patients was significantly lower than that of PD-L1-negative patients. The K-ras gene mutation rate was 35.6%, and the main mutation site was in codon 12. The positive PD-L1 expression rate in patients with K-ras gene mutations was significantly higher than that in patients with wild-type K-ras gene mutations. CONCLUSION: PD-L1 is highly expressed in colorectal cancer, and its expression is related to metastasis and tumor stage. PD-L1 expression is closely related to K-ras gene mutation, and the K-ras gene status may affect PD-L1 expression. TRIAL REGISTRATION: retrospectively registered. AJTR
OBJECTIVE: To detect the expression of PD-L1 and K-ras gene status in colorectal cancer tissues and analyze the relationship between PD-L1 expression and the clinicopathological features and K-ras gene status in colorectal cancer. METHODS: Two hundred fifty colorectal cancer tissues were collected from the First Affiliated Hospital of Nanchang University. The normal intestinal mucosal tissues of 20 patients were randomly selected for inclusion in the control group. PD-L1 expression was detected by immunohistochemistry. K-ras gene mutation in colorectal cancer tissues was detected by sequencing. The clinical significance of PD-L1 expression and relationship between PD-L1 expression and K-ras gene mutation were analyzed. RESULTS: The immunohistochemistry assay showed that PD-L1 was highly expressed in colorectal cancer. The positive expression of PD-L1 was increased with lymph node metastasis and high TNM stage. The 5-year survival rate of PD-L1-positive patients was significantly lower than that of PD-L1-negative patients. The K-ras gene mutation rate was 35.6%, and the main mutation site was in codon 12. The positive PD-L1 expression rate in patients with K-ras gene mutations was significantly higher than that in patients with wild-type K-ras gene mutations. CONCLUSION:PD-L1 is highly expressed in colorectal cancer, and its expression is related to metastasis and tumor stage. PD-L1 expression is closely related to K-ras gene mutation, and the K-ras gene status may affect PD-L1 expression. TRIAL REGISTRATION: retrospectively registered. AJTR
Authors: Lindsey A Torre; Freddie Bray; Rebecca L Siegel; Jacques Ferlay; Joannie Lortet-Tieulent; Ahmedin Jemal Journal: CA Cancer J Clin Date: 2015-02-04 Impact factor: 508.702
Authors: Joannes F M Jacobs; Albert J Idema; Kalijn F Bol; Stefan Nierkens; Oliver M Grauer; Pieter Wesseling; J André Grotenhuis; Peter M Hoogerbrugge; I Jolanda M de Vries; Gosse J Adema Journal: Neuro Oncol Date: 2008-11-21 Impact factor: 12.300
Authors: Jonna Berntsson; Jakob Eberhard; Björn Nodin; Karin Leandersson; Anna H Larsson; Karin Jirström Journal: Oncoimmunology Date: 2018-06-11 Impact factor: 8.110